Christine Aylward founded Magnetic Ventures in 2018 and focuses on early stage investing at the intersection of life science and technology. She has worked at the forefront of healthcare innovation since the start of her career and has been in the venture capital business since 2011. Christine has a proven track record of investing in healthcare winners, deep domain expertise, and industry operating experience commercializing global franchises and building companies. She started her career at Roche where she launched the revolutionary technology polymerase chain reaction (PCR), formed the first cross collaboration between the pharmaceutical and diagnostic divisions, was a key member of several marketing teams at Roche Pharmaceuticals, Roche Diagnostics and Roche Molecular Systems, and was placed on the Executive Development Track. Christine has helped launch more than 20 products in the pharmaceutical, genomics, healthcare technology and diagnostic sectors.
Most recently, Christine was a Managing Director, member of the investment team, and head of Business Development at Foresite Capital. While there, Christine was instrumental in building the firm to $1.2 billion in assets under management over five years, and helped identify and grow some of the most valuable companies within the portfolio, including Aimmune (Nasdaq: AIMT) and 10x Genomics (Nasdaq: TXG). Christine has also been an entrepreneur in the media sector, and was a partner at a technology-focused investment bank acquired by Goldman Sachs. As a founder, business executive and investor, Christine not only has a unique lens to evaluate companies but is also an invaluable resource for the entrepreneurs in which she invests. Her meaningful relationships and expertise span pharmaceuticals, diagnostics, genomics, technology, and finance.